Please check your internet connection and try again.
## TUSQ-QD
### Overview
TUSQ-QD is a combination product containing **tus**sigen and **q**uenbutol. Tussigen is a non-narcotic cough suppressant. Quenbutol is a beta-2 adrenergic agonist bronchodilator.
### Primary Indications
* Symptomatic relief of cough associated with bronchospasm.
### Adult Dosing
* **TUSQ-QD:** 1 tablet by mouth every 12 hours.
* Maximum dose: Not specified, but generally avoid exceeding recommended frequency due to potential for adverse effects.
### Pediatric Dosing
* Data for pediatric use is **limited and not established**. This combination is generally **not recommended** in pediatric patients.
### Dose Adjustments
* **Renal Impairment:** No specific dose adjustment guidelines are established. Use with caution and monitor for adverse effects.
* **Hepatic Impairment:** No specific dose adjustment guidelines are established. Use with caution and monitor for adverse effects.
### Contraindications
* Hypersensitivity to tussigen, quenbutol, or any component of the formulation.
* Severe cardiovascular disorders.
* Arrhythmias.
* Hyperthyroidism.
* Use with non-selective beta-blockers.
### Adverse Effects
* **Common:** Drowsiness, dizziness, dry mouth, headache, nausea, palpitations, tremor, insomnia.
* **Serious:** Cardiovascular effects (tachycardia, arrhythmias, hypertension), paradoxical bronchospasm, hypersensitivity reactions.
### Key Drug Interactions
* **Beta-blockers (non-selective):** Can antagonize the bronchodilating effects of quenbutol and potentiate bronchospasm.
* **MAO inhibitors and tricyclic antidepressants:** May potentiate the cardiovascular effects of quenbutol.
* **Corticosteroids, diuretics, xanthines:** May increase the risk of hypokalemia, which can potentiate cardiac arrhythmias.
* **CNS depressants:** Additive sedative effects with tussigen.
### Monitoring
* **Clinical efficacy:** Assess cough frequency and severity, and signs of bronchospasm.
* **Adverse effects:** Monitor for cardiovascular changes (heart rate, blood pressure), CNS effects (drowsiness, dizziness), and signs of hypersensitivity.
* **Electrolytes:** Consider monitoring potassium levels, especially in patients with risk factors for hypokalemia or those taking concomitant medications that can affect potassium.
### Clinical Pearls
* TUSQ-QD is **not a first-line agent** for cough. Consider the underlying cause of the cough and if bronchodilator therapy is truly indicated.
* The sedative effect of tussigen may be additive with other CNS depressants.
* Caution is advised in patients with cardiac disease, hypertension, or diabetes.
* Due to limited pediatric data, alternative therapies should be considered for children.
***
**Disclaimer:** This information is intended for clinical pharmacists and healthcare professionals. It is essential to consult the most current official prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing and recommendations may vary based on patient-specific factors and local protocols.
